Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Tucatinib|DRUG: Capecitabine|DRUG: Trastuzumab
Sponsor: Seagen Inc.
Collaborators: Parexel